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Abstract
Background: Increased use of analgesics in the population is a cause for concern in terms of drug safety. There is a
paucity of population-based studies monitoring the change in use over time of both non-prescription (OTC) analgesics
and prescription (Rx) analgesics. Although much is known about the risks associated with analgesic use, we are lacking
knowledge on high-risk use at a population level. The purpose of this study was to estimate the prevalence of
non-prescription and prescription analgesic use, change over time and the prevalence in the presence of potential
contraindications and drug interactions in a general population.
Methods: A repeated cross-sectional study with data from participants (30–89 years) of the Tromsø Study in 2001–02
(Tromsø 5; N = 8039) and in 2007–08 (Tromsø 6; N = 12,981). Participants reported use of OTC and Rx analgesics and
regular use of all drugs in the preceding four weeks. Change over the time period was analyzed with generalized
estimating equations. The prevalence of regular analgesic use in persons with or without a clinically significant
contraindication or drug interaction was determined in the Tromsø 6 population, and differences were tested with
logistic regression.
Results: Analgesic use increased from 54 to 60 % in women (OR = 1.24, 95 % CI 1.15–1.32) and from 29 to 37 % in men
(OR = 1.39, 95 % CI 1.27–1.52) in the time period; the increase was due to sporadic use of OTC analgesics. There was
substantial regular use of analgesics in several of the contraindication categories examined; the prevalence of
non-steroidal anti-inflammatory drugs was more than eight per cent among persons with chronic kidney disease,
gastrointestinal ulcers, or high primary cardiovascular risk. About four per cent of the study population demonstrated at
least one potential drug interaction with an analgesic drug.
Conclusions: The use of analgesics increased in the time period due to an increase in the use of OTC analgesics.
Analgesic exposure in the presence of contraindications or drug interactions may put patients at risk. Public and
prescriber awareness about clinically relevant contraindications and drug interactions with analgesics need to be
increased.
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Background
The availability of analgesics has increased in Norway
due to a major rise in the number of pharmacies since
2001 and the release of ibuprofen and paracetamol to
general sales in supermarkets, grocery stores and petrol
stations in 2003 [1]. The sales of analgesics has increased
considerably in Norway over the last decades [2]. The
prevalence of analgesic use has been examined in several
international cross-sectional studies [3–10]. However,
there is a paucity of population-based studies monitoring
the change in use over time of both OTC analgesics and
prescription (Rx) analgesics.
Increased use of analgesics in the population is a cause
for concern in terms of drug safety. Paracetamol and in par-
ticular non-steroidal anti-inflammatory drugs (NSAIDs)
and opioids are among the drugs that are most often impli-
cated in serious or fatal medication errors [11]. NSAID use
is associated with increased risk of cardiovascular disease
(CVD) [12–14], gastrointestinal damage [15], renal disease
[16, 17] and a number of drug interactions [15, 18]. Opioids
have an abuse potential but few adverse effects when used
correctly. They can, however, produce respiratory depres-
sion [15, 19] and increase the risk of falls and subsequent
injuries [20], particularly in combinations with other central
nervous system (CNS) depressant drugs [19]. Paracetamol,
although considered safe in recommended doses, is hepato-
toxic in high doses and can give rise to drug induced liver
injury [21]; there is some concern about a possible associ-
ation with increased CVD risk [22]. The potential inappro-
priate use of analgesics in the general population has
previously been reported in smaller studies of variable rigor,
most of them focusing on OTC analgesics [7, 23–27].
This study aimed to estimate the prevalence of OTC
and Rx analgesic use, change over time and the preva-
lence of use in the presence of potential contraindica-
tions and pharmacodynamic drug interactions.
Methods
Study population
The Tromsø Study is a population-based study of vari-
ous health issues and diseases. It consists of six surveys
(Tromsø 1–6) carried out in the municipality of Tromsø,
Norway, from 1974 to 2008 [28]. Eligible for the present
study were participants from Tromsø 5 (2001–02, N =
8039) and Tromsø 6 (2007–08, N = 12,981), aged 30–89
years (Fig. 1). The participants in Tromsø 5 and Tromsø
6 consisted of persons who attended a second visit in
Tromsø 4 in 1994–5 (i.e. all Tromsø inhabitants aged
55–74 years, and a 5–10 % random sample of those 25–
50 and 75–85 years of age were invited), in addition to
whole birth cohorts or random samples of birth cohorts
(see [28, 29] for further explanation). A total of 4630 in-
dividuals participated in both Tromsø 5 and Tromsø 6.
The data collection is described elsewhere [29]. An
English translation of the questionnaires is available at
the Tromsø Study homepage (www.tromsostudy.com).
Definition of analgesic use
Analgesic use was assessed through questionnaire based
on the question “How often have you used painkillers
[with]/[without] prescription during the last four weeks?”
(Fig. 1). Analgesic users were defined as persons reporting
any use. This variable was recoded into use of OTC anal-
gesics only (“OTC”), use of prescribed analgesics only
(“Rx”) and use of concomitantly OTC and prescribed anal-
gesics (“OTC+Rx”; Fig. 1).
Participants in Tromsø 6 also reported drugs used
regularly the preceding four weeks; this was coded ac-
cording to the Anatomical Therapeutic Chemical (ATC)
classification system version 2007 (www.whocc.no). An-
algesics were defined as belonging to ATC groups N02B
(other antipyretic and analgesic drugs), N02A (opioids)
and M01A (NSAIDs, excluding glucosamine).
Criteria for contraindications and drug interactions
The analyses of potential contraindications and drug in-
teractions were done among participants in Tromsø 6
(Fig. 1). A contraindication was defined as a condition
that indicates that a drug should not be used. The cri-
teria were developed a priori, based on literature and
available variables:
Chronic kidney disease: estimated glomerular filtration
rate (eGFR) < 60 ml/min per 1.73 m2 or ≥ 60 ml/min per
1.73 m2 and either macroalbuminuria or persistent
microalbuminuria [30]. EGFR was estimated by the
CKD-EPI equation [31]. Gastrointestinal ulcers: self-
reported stomach or duodenal ulcer or ulcer surgery. A
secondary measure was use of H2 antagonists, misopros-
tol or proton pump inhibitors (ATC codes A02B A,
A02B B, A02B C, respectively). CVD: NORRISK cardio-
vascular risk score estimates the 10-year risk of fatal
CVD, using sex, age, systolic blood pressure, total chol-
esterol and smoking [32]. The primary CVD risk group
was defined as individuals with no prior myocardial in-
farction (MI), angina pectoris or stroke, aged 40–49
years and with a NORRISK score > 1 %; 50–59 years and
NORRISK score ≥ 5 %; or 60–69 years and NORRISK
score ≥ 10 % according to national guidelines [33]. The
secondary CVD risk group consisted of those with a his-
tory of stroke, MI or angina pectoris. Hypertension: sys-
tolic blood pressure ≥ 140 mmHg or diastolic blood
pressure ≥ 90 mmHg or self-reported current use of anti-
hypertensive drugs. Interacting drugs: warfarin (B01A
A03), low-dose acetylsalicylic acid (ASA; B01A C06),
selective serotonin reuptake inhibitors (SSRI; N06A B),
glucocorticoids (H02A B), angiotensin converting enzyme
(ACE) inhibitors (C09A, C09B), angiotensin II (AT II)
antagonists (C09C, C09D), other antihypertensive drugs
Samuelsen et al. BMC Pharmacology and Toxicology  (2015) 16:16 Page 2 of 10
(C02, C03, C07, C08) and CNS depressant drugs (N05C
A-F, N05B A, N03A E, N03A A). Use of multiple analge-
sics: regular use of more than one analgesic drug within
the same pharmacological group: NSAIDs, opioids and
paracetamol-containing drugs (N02B E01 and N02A A59).
Statistical analysis
Descriptive statistics were age-adjusted with logistic re-
gression (adjprop command). The changes in preva-
lences between Tromsø 5 and Tromsø 6 were tested
with generalized estimating equations (GEE) and esti-
mated as odds ratios (ORs) with 95 % confidence inter-
vals (CI) using a logit link function, exchangeable
covariance matrix and robust standard errors; separate
binary GEE models were fitted for each prescription cat-
egory with non-users of both OTC and Rx as the refer-
ence group. The prevalence measures were age-adjusted
by the direct method, with the Norwegian population
per 01.01.2008 as standard population [34]. Linear age
trends across age groups were tested with logistic regres-
sion. Sex differences in age-adjusted prevalences were
tested with two-sample proportion test (Z test) and
crude prevalences with Fisher’s exact test. Differences in
analgesic use in the absence or presence of contraindica-
tions or drug interactions were tested with logistic re-
gression and likelihood ratio test, adjusted for age and
sex (adjprop). All analyses were complete case analyses.
The overall proportion of missing data in the dependent
variables in the GEE analyses was 12.0 % in Tromsø 5 and
3.9 % in Tromsø 6 (Fig. 1). Sensitivity analyses by imputing
missing values as non-user or user, were generally consist-
ent with the main results. All analyses were conducted in
Stata 13.1 (Stata Corp, College Station, Texas).
Ethics
This study has been approved by the Regional Committee
for Medical and Health Research Ethics, North Norway
(2012/1636), and was performed in accordance with the
1964 Helsinki declaration and its later amendments. In-
formed consent was obtained from all individual partici-
pants included in the study.
Fig. 1 Flow chart of the study and questionnaire items. OTC = “over-the-counter”, non-prescription; Rx = prescription; NSAIDs = non-steroidal
anti-inflammatory drugs
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Results
There was a tendency of worsening health, more pain and
less education across the analgesic user groups, from non-
users to users of OTC + Rx analgesics (Table 1).
Women used more analgesics than men, both in total
and in all prescription categories, in both surveys
(Table 2). The total analgesic use decreased with age in
both sexes and in both surveys (p < .001). The use of
OTC decreased, whereas Rx increased with age in both
sexes and in both surveys.
The total use of analgesics and the use of OTC in-
creased in the time period (Table 2). Total use increased
from 53.7 to 59.6 % in women and from 29.1 to 36.7 %
in men, corresponding to OR = 1.24, 95 % CI 1.15–1.32
and OR = 1.39, 95 % CI 1.27–1.52, respectively. The use
of Rx analgesics did not show any change, while the use
of OTC + Rx analgesics increased in both women and
men. When the analyses were restricted to frequent
users, defined as daily or weekly users, there was no
change in total use (data not shown).
The crude prevalences of regular use of NSAIDs, other
analgesics and antipyretics, and opioids were 12.7 % (n =
1646), 12.5 % (n = 1624) and 3.7 % (n = 475), respectively.
The prevalences of cyclooxygenase 2 (COX-2) inhibitors
and high-dose ASA use were 0.1 % (n = 13) and 0.2 % (n =
31), respectively. The use of NSAIDs and other analgesics
decreased with age in both sexes (p < .001), while opioid
use increased in women (p = .048) and decreased in men
(p = .027; Fig. 2). More women than men used analgesics
regularly (p < .001). The sex difference for opioids was only
apparent in the highest age groups (≥60 years).
Table 3 shows the prevalence of regular analgesic use
in the absence or presence of contraindications. The
prevalence was high in several of the contraindication
groups; for the important contraindications chronic kid-
ney disease, gastrointestinal ulcer diseases and high
Table 1 Charactheristics of non-users and users of OTC, Rx, or combined OTC + Rx analgesics
Non-users OTC Rx OTC + Rx
% (n) % (n) % (n) % (n)
Analgesic use (n = 12,481)a 53.8 (6719) 31.7 (3957) 5.1 (641) 9.3 (1164)
Sex, % women (n = 12,481) 41.8 (2818) 65.1 (2561) 58.6 (378) 70.8 (824)
Age (n = 12,481)
30–39 3.2 (213) 6.2 (247) 1.2 (8) 3.3 (38)
40–49 23.1 (1549) 37.4 (1479) 20.7 (133) 31.4 (365)
50–59 18.4 (1236) 20.5 (813) 16.8 (108) 18.1 (211)
60–69 35.5 (2388) 24.7 (979) 35.7 (229) 28.4 (330)
70–79 15.5 (1041) 8.8 (347) 20.1 (129) 14.8 (172)
80–87 4.3 (292) 2.3 (92) 5.3 (34) 4.1 (48)
Mean (SD), 30–87 years 58.9 (12.3) 53.6 (12.3) 60.8 (12.0) 57.1 (12.8)
Bad or very bad self-reported health (n = 12,390) 3.2 (226) 4.3 (162) 10.1 (70) 15.9 (185)
Education below college or university (n = 12,341) 59.9 (4029) 63.0 (2278) 69.4 (451) 74.3 (827)
Smoking, current daily (n = 12,329) 18.1 (1194) 21.1 (873) 24.1 (146) 27.5 (318)
Pain lasting three months or more (n = 12,462) 19.9 (1344) 35.6 (1393) 63.1 (404) 74.7 (868)
Headache, last year (n = 11,472) 18.5 (1156) 50.0 (1928) 46.7 (257) 61.3 (645)
Severe pain or stiffness in muscles, last four weeks
Neck (n = 10,665) 4.2 (243) 9.6 (326) 20.1 (104) 29.5 (289)
Hip/leg (n = 10,531) 3.8 (237) 7.8 (249) 20.5 (122) 28.9 (280)
Psychological distressb (n = 11,941) 5.4 (343) 8.7 (340) 11.4 (67) 20.9 (230)
Frequent GP consultations, last 12 monthsc (n = 9335) 10.9 (538) 11.6 (343) 19.7 (105) 25.2 (243)
Drug use, last four weeks
Antidepressants (n = 12,195) 1.6 (116) 2.9 (106) 4.3 (29) 9.0 (97)
Sleeping pills or tranquilizers (n = 12,164) 5.7 (476) 12.0 (445) 14.8 (112) 27.3 (297)
Age-adjusted. The Tromsø Study: Tromsø 6 (2007–8, n = 12,481)
OTC “over-the-counter”, non-prescription, Rx prescription, SD standard deviation, GP general practitioner
aCrude prevalence
bHopkins Symptoms Checklist 10-item version > 1.85
c≥ 6 visits per year (>90th percentile)
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Table 2 Prevalence of analgesic use and change over time
Population OTC only Rx only OTC + Rx Total
Survey T5 T6 T5 T6 T5 T6 T5 T6 T5 T6
Age (years) n (%) n (%) % % OR (95 % CI)a % % OR (95 % CI)a % % OR (95 % CI)a % % OR (95 % CI)a
Women
30–39 408 (10.4) 295 (4.5) 46.3 55.6 1.45 (1.05–1.99) 2.2 1.4 0.75 (0.23–2.48) 10.3 9.2 1.09 (0.63–1.86) 58.8 66.1 1.37 (1.00–1.86)
40–49 710 (18.1) 1880 (28.6) 44.9 49.3 1.29 (1.07–1.56) 5.2 3.8 0.87 (0.57–1.31) 10.9 13.6 1.41 (1.08–1.84) 61.0 66.6 1.29 (1.08–1.53)
50–59 637 (16.2) 1245 (18.9) 32.2 43.6 1.68 (1.36–2.07) 6.0 5.1 1.05 (0.68–1.61) 12.7 11.7 1.85 (0.71–4.80) 50.9 60.4 1.49 (1.23–1.79)
60–69 1187 (30.2) 1987 (30.2) 29.0 31.4 1.11 (0.96–1.29) 7.6 7.1 0.96 (0.74–1.24) 11.2 11.5 1.01 (0.83–1.22) 47.8 50.0 1.06 (0.94–1.21)
70–79 871 (22.2) 886 (13.5) 23.7 26.1 1.16 (0.94–1.43) 9.5 8.5 0.95 (0.69–1.31) 11.5 14.3 1.25 (1.00–1.56) 44.7 48.9 1.14 (0.96–1.36)
80+ 118 (3.0) 288 (4.4) 25.4 25.7 1.15 (0.68–1.92) 5.9 8.3 1.18 (0.80–1.77) 15.3 13.9 0.98 (0.53–1.82) 46.6 47.9 1.15 (0.76–1.74)
30–89 3931 (100) 6581 (100) 32.9 38.9 1.26 (1.17–1.36) 6.7 5.7 0.98 (0.84–1.14) 11.5 12.5 1.19 (1.08–1.30) 51.1 57.2 1.21 (1.13–1.30)
Age–adjustedb 36.7 42.9 1.30 (1.20–1.41) 5.5 4.8 0.98 (0.84–1.14) 11.5 11.9 1.20 (1.09–1.32) 53.7 59.6 1.24 (1.15–1.32)
p, age trend <.001 <.001 <.001 <.001 .370 .471 <.001 <.001
Men
30–39 273 (8.7) 211 (3.6) 30.4 39.3 1.58 (1.08–2.30) 1.8 1.9 1.23 (0.32–4.64) 4.4 5.2 1.40 (0.60–3.29) 36.6 46.5 1.55 (1.08–2.22)
40–49 569 (18.1) 1646 (27.9) 27.2 33.6 1.45 (1.18–1.78) 2.6 3.8 1.69 (0.97–2.95) 3.3 6.7 2.39 (1.45–3.94) 33.2 44.1 1.56 (1.29–1.89)
50–59 332 (10.6) 1123 (19.0) 18.4 24.0 1.34 (1.01–1.79) 6.3 4.0 0.68 (0.42–1.13) 2.4 5.8 2.63 (1.25–5.51) 27.1 33.8 1.29 (1.01–1.65)
60–69 1108 (35.2) 1939 (32.9) 14.0 18.4 1.37 (1.13–1.66) 5.7 4.5 0.84 (0.61–1.15) 4.5 5.2 1.19 (0.87–1.63) 24.2 28.1 1.21 (1.04–1.41)
70–79 769 (24.5) 803 (13.6) 10.4 14.5 1.52 (1.13–2.06) 5.6 6.7 1.31 (0.88–1.94) 4.3 5.6 1.43 (0.91–2.24) 20.3 26.8 1.46 (1.17–1.83)
80+ 94 (3.0) 178 (3.0) 10.6 10.1 0.93 (0.42–2.05) 7.5 5.6 0.75 (0.28–2.05) 1.1 4.5 4.27 (0.53–34.60) 19.2 20.2 1.05 (0.56–1.96)
30–89 3145 (100) 5900 (100) 17.3 23.7 1.46 (1.32–1.61) 4.9 4.5 1.02 (0.84–1.23) 3.9 5.8 1.59 (1.31–1.92) 26.1 33.9 1.38 (1.27–1.50)
Age–adjustedb 21.3 27.1 1.48 (1.33–1.65) 4.3 3.9 1.03 (0.85–1.24) 3.5 5.7 1.57 (1.29–1.91) 29.1 36.7 1.39 (1.27–1.52)
p, age trend <.001 <.001 .001 .001 .727 .127 <.001 <.001
p, sex <.001 <.001 .037 .046 <.001 <.001 <.001 <.001
The proportion of analgesic users last four weeks and odds ratios for use of analgesics in Tromsø 6 compared to Tromsø 5, according to age, sex and prescription category. The Tromsø Study: Tromsø 5 (2001–02,
n = 7076) and Tromsø 6 (2007–08, n = 12,481)
OTC “over-the-counter”, non-prescription, Rx prescription, T5 Tromsø 5, T6 Tromsø 6, CI confidence interval, OR odds ratio
aReference category: non-users of both OTC and Rx















Fig. 2 Regular analgesic use, both non-prescription and prescribed, last four weeks according to age and sex. The Tromsø Study: Tromsø 6 (N = 12
981). Other analgesics and antipyretics (long dashed line), non-steroidal anti-inflammatory drugs (solid line) and opioids (short dashed line). Vertical lines
are the 95 % confidence intervals. “Other” include paracetamol (which constitutes over 95 %), high-dose acetylsalicylic acid and phenazone-caffeine
Table 3 Regular use of analgesics in the absence or presence of contraindications
Unadjusted Age- and sex-adjusted
Contraindicationa Absent Present Absent Present p value Potential clinical consequence
% (n) % (n) % %
Non-steroidal anti-inflammatory drugs
Chronic kidney disease (6834/10.1) 11.2 (686) 8.6 (59) 11.6 12.0 .802 Acute renal failure, disease progression
GI ulcers
Ulcers (11,516/7.4) 12.8 (1365) 12.0 (102) 11.8 12.6 .509 GI ulceration and complications
Ulcers or use of GI-protective drugs (11,516/10.7) 12.7 (1301) 13.4 (166) 11.6 14.1 .014 GI ulceration and complications
CVD
High primary CVD risk (9000/13.0) 14.4 (1125) 11.1 (129) 12.1 13.5 .220 Increased risk of CVD
Stroke, MI, angina pectoris (12,540/9.6) 13.3 (1506) 6.7 (80) 12.1 8.8 .003 Increased risk of CVD
Hypertension (12,725/49.1) 14.2 (922) 11.3 (705) 11.5 12.5 .122 Increased blood pressure
Paracetamol
CVD
High primary CVD risk (9000/13.0) 14.5 (1139) 9.7 (113) 11.6 12.6 .401 Possible increased risk of CVD
Stroke, MI, angina pectoris (12,540/9.6) 13.8 (1565) 9.9 (119) 12.3 12.8 .712 Possible increased risk of CVD
The Tromsø Study: Tromsø 6 (N = 12,981)
GI gastrointestinal, CVD cardiovascular disease, MI myocardial infarction
aNumbers in parentheses are total n in variable and prevalence (%) in the study population
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primary cardiovascular risk there were no differences in
regular NSAID use between those with and without the
contraindication, when adjusting for age and sex differ-
ences. Among the categories examined, only persons
with a history of CVD had a lower prevalence of NSAID
use compared to those without a CVD history.
Four hundred and sixteen instances of use of multiple
analgesics were found in 384 persons; the proportions
were 11.2 % (n = 184) in NSAID users, 12.0 % (n = 209)
in users of paracetamol-containing analgesics and 4.8 %
(n = 23) in opioid users.
Table 4 shows the prevalence of regular analgesic use
in the absence or presence of interacting drugs. In total
4.1 % (n = 538) of the population presented at least one
of the identified potential drug interactions. One percent
presented more than one potential drug interaction. For
interactions potentially increasing the bleeding risk, the
use of NSAIDs was the same or higher among users of
glucocorticoids or SSRIs, respectively. The use of NSAIDs
was comparatively lower for patients using the anticoagu-
lant warfarin and low-dose ASA.
Discussion
The use of analgesics increased from 2001–02 to 2007–
08, due to an increase in the use of OTC analgesics. The
prevalence of regular analgesic use in the contraindica-
tion categories examined was more than six per cent,
and about four per cent of the study population pre-
sented at least one potential drug interaction with an an-
algesic drug. In particular, the use of NSAIDs in the
presence of chronic kidney disease, gastrointestinal
ulcers, high primary risk of CVD and interacting drugs
increasing the bleeding risk was a cause for concern.
The sales of NSAIDs more than doubled, paracetamol
tripled, while high-dose ASA declined substantially in
Norway from 1990 to 2013 [2]. A comparison of our data
with data from the 1980s and 1990s [3–5, 10], and studies
on changes in Rx analgesic use [35–37] points towards an
increase in analgesic use from the 1980s to the present.
However, a US study employing data from around 1990
shows much higher use of OTC analgesics in correspond-
ing age groups compared to our findings, whereas the use
of Rx analgesics was lower in women and comparable in
men [6], suggestive of a different usage pattern in the US.
We found no increase in frequent analgesic use in the
time period, reflecting that the increase was due to spor-
adic use of OTC analgesics. Possible hypotheses for the
trend in analgesic use include increased prevalence of
pain, a shift in the attitude towards perceived pain and/or
drug use, and increased availability. It has been previously
shown that a switch to OTC status leads to an initial in-
crease in total sales of the drug [38], while the release to
general sales may increase the use of NSAIDs [26]. How-
ever, the possible link between increased availability and
increased use warrants further research.
Users of OTC NSAIDs are generally unaware of or un-
concerned with the potential harmful effects, as OTC
drugs are perceived to be relatively safe [27]. The recom-
mended doses of OTC NSAIDs are lower than the rec-
ommended prescription doses. However, use of OTC
analgesics in doses exceeding the maximum has been re-
ported [27].
Table 4 Regular use of analgesics in the absence or presence of interacting drugs
Unadjusted Age- and sex-adjusted
Interacting druga Absent Present Absent Present p value Potential clinical consequence
% (n) % (n) % %
Non-steroidal anti-inflammatory drugs
Warfarin (2.5) 12.9 (1637) 2.8 (9) 12.1 3.9 <.001 Increased bleeding risk
ASA, low dose (11.7) 13.6 (1558) 5.8 (88) 12.5 7.4 <.001 Increased bleeding risk
SSRI (1.5) 12.5 (1602) 22.0 (44) 11.8 19.5 .001 Increased bleeding risk
Glucocorticoids (1.3) 12.7 (1625) 12.6 (21) 11.9 13.0 .672 Increased bleeding risk
ACE inhibitors (3.8) 12.9 (1614) 6.5 (32) 12.0 7.8 .007 Diminished effect, renal impairment, hyperkalemia
AT II antagonists (9.2) 12.8 (1508) 11.5 (138) 11.8 12.8 .326 Diminished effect, renal impairment, hyperkalemia
Other antihypertensives (18.8)b 13.3 (1397) 10.2 (249) 11.8 12.1 .693 Diminished effect
Opioids
CNS depressants (4.9)c 2.9 (359) 18.1 (116) 2.9 17.5 <.001 CNS depression, respiratory depression, falls
Paracetamol
Warfarin (2.5) 13.6 (1719) 7.1 (23) 12.5 9.5 .154 Increased bleeding risk
The Tromsø Study: Tromsø 6 (N = 12,981)
ASA acetylsalicylic acid, SSRI selective serotonin reuptake inhibitors, ACE angiotensin converting enzyme, AT II angiotensin II, CNS central nervous system
aThe number in parentheses is the prevalence (%) in the study population
bATC-groups C02, C03, C07, C08
cBenzodiazepines, z hypnotics and barbiturates (ATC-groups N05C A-F, N05B A, N03A E, N03A A)
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For most of the contraindications examined, the
prevalence of analgesic use was not different between
persons with and without the condition when adjusted
for age and sex differences. This suggests lack of awareness
about the contraindications. We demonstrated frequent
use of multiple analgesics within the same pharmacological
group, in line with previous studies [25, 26], and frequent
combined use of OTC and Rx analgesics; this would be
expected to increase the risk of dose-dependent adverse
effects.
NSAID use is associated with further renal impairment
in individuals with underlying kidney disease [15], acute
renal failure [16] and progression of chronic kidney dis-
ease [17]. We found no difference in regular use of
NSAIDs among those with and without chronic kidney
disease, in line with previous research [39]. Some eight
percent (n = 59) of subjects reported using NSAIDs regu-
larly despite having chronic kidney disease, putting them
at risk of disease progression and acute renal failure.
The use of NSAIDs was not affected by a history of
gastrointestinal ulcers. However, the prevalence of
NSAID use was higher in patients using gastroprotective
agents than in non-users. The use of gastroprotective
agents may be considered either as a marker of gastrointes-
tinal disease, i.e. a risk factor, or as a prudent precautionary
measure, i.e. the prophylactic use of gastroprotective agents
in persons at increased risk.
The prevalence of NSAID use was lower in persons
with a history of CVD compared with those with no
CVD. The risk of CVD is increased by most NSAIDs,
even as short-term treatment and both in healthy indi-
viduals and in those with known CVD [12, 14] or high
CVD risk [13]. There were almost no users of COX-2 in-
hibitors in our study population. However, diclofenac is
comparable to the COX-2 inhibitors in terms of CVD risk
[12]. Diclofenac is the second most sold NSAID in Norway
[2] and has been available as an OTC drug from 2001.
If our data are applied to the entire Norwegian popula-
tion per 2008 [34], approximately 25,000 persons aged
40–69 years with high primary CVD risk would be regu-
lar NSAID users. The NORRISK equation overestimates
the prevalence of high primary CVD risk, but neverthe-
less our results suggest that being at high primary CVD
risk does not lead to lower NSAID use. This constitutes
an important problem even when the absolute risks in
the population decrease.
Low-dose ASA, glucocorticoids, SSRIs, and in particu-
lar warfarin increase the gastrointestinal bleeding risk
when combined with NSAIDs [15]. The much lower
prevalence of NSAID use among warfarin users may be
due to prescriber diligence and frequent consultations
with this group of patients. Our results do however sug-
gest that the concomitant use of glucocorticoids or
SSRIs with NSAIDs is not perceived as problematic.
The prevalence of NSAID use was lower among pa-
tients taking ACE inhibitors compared to non-users,
while no such difference was found for the AT II antago-
nists. This is somewhat surprising, as the combination
of either ACE inhibitors or AT II antagonists with
NSAIDs is associated with both diminished antihyper-
tensive efficacy as well as an increased risk of renal im-
pairment and hyperkalemia [18].
Our results show a high degree of co-medication with
CNS depressant drugs among opioid users, in agreement
with previous research [40]. The combination with other
CNS depressant drugs increases respiratory depression
[15, 19] and the risk of fractures [20], and can be sug-
gestive of substance abuse [19], as well as be detrimental
on activities requiring alertness, i.e. driving.
This observational study has some limitations. Our
analyses included data from two cross-sections of the
Tromsø study; inferences on causality are difficult if not
impossible due to the lack of temporality between ex-
posure and effect.
The agreement between self-reported analgesic use
and prescription records is moderate [41]. The rate of
underreporting of self-reported use of ibuprofen and
paracetamol is approximately 15 % or more [42]. Recall
of NSAID use declines over time, and particularly
among infrequent users of OTC NSAIDs [43]. Higher
use of strong analgesics among non-participants com-
pared to participants has been reported [9]. This all
points toward an underestimation of the prevalence of
analgesic use in the present study.
Participants reported the use of “painkillers”, leading
to possible ambiguity and misclassification. We could
not separate OTC and Rx use in the analyses on high-
risk use. The contraindications and drug interactions
identified may have been dealt with in an adequate man-
ner by the prescribing physician or other health
personnel. The most severe cases may have been missed
due to non-participation, leading to an underestimation
of high-risk analgesic use.
Study strengths include the use of a large, repeated
population-based survey and self-reported data on both
OTC analgesics and Rx analgesics. A comprehensive es-
timate of the use of analgesics cannot be done without
the use of interview or questionnaires.
The Tromsø population may be regarded as represen-
tative of a Northern European, white, urban population
[29], and the results may be generalizable to such
populations.
Conclusions
The use of analgesics increased in the time period, in
line with other studies and gross sales statistics, mainly
due to an increase in sporadic use of OTC analgesics.
We have identified several areas of high risk use of
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analgesics where a known contraindication or drug
interaction do not seem to lead to lower use at a popula-
tion level. This could put people at risk and pose a
threat to public health. Public and prescriber awareness
about important contraindications, such as chronic kid-
ney disease, gastrointestinal ulcers and risk of CVD, as
well as clinically relevant drug interactions with analge-
sics, need to be increased.
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